Respiratory diseases affect all age groups, with more than 65 million people in Europe being affected and 1 in 7 deaths being caused by chronic lung disease. Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disorder and the fourth leading cause of death in Europe. For the purposes of this report, COPD is defined as chronic airway obstruction that results from chronic bronchitis, emphysema, or a combination of these diseases. COPD treatment products covered by this report include oxygen therapy products, blood gas monitoring systems, airway management accessories, and spirometry testing products. In 2011, European sales of these products totaled nearly $2.0 billion. Over the forecast period covered by this report, sales are expected to increase at a compound annual rate of 5.9%, reaching an estimated $2.7 billion in the year 2016.
This new report by Medtech Insight presents a detailed overview of the European COPD treatment products market. Major topics covered by this report include an overview of respiratory diseases including European disease incidence and prevalence figures, oxygen therapy systems (e.g., oxygen concentrators and liquid oxygen systems), blood gas monitoring systems (e.g., POC analyzers, laboratory analyzers, arterial blood gas sampling kits, intra-arterial analyzers, pulse oximeters, and capnographers), airway management accessories (e.g., heat/moisture exchangers, humidifiers, nebulizers, and respiratory masks), and spirometry testing products (e.g., diagnostic and incentive spirometers).
Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.